World's Best Scientists 2026 revealed!
Zobair M. Younossi

Zobair M. Younossi

D-Index & Metrics

Medicine

D-Index
138
Citations
121953
World Ranking
1787
National Ranking
1021

Overview

Zobair M. Younossi is affiliated with the Inova Health System in the United States and has published extensively in the field of medicine, with a particular focus on liver diseases. Their scholarly work spans multiple subfields including epidemiology, hepatology, endocrinology, diabetes and metabolism, surgery, and pathology and forensic medicine.

Their research covers several main topics, such as:

  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Liver Diseases and Immunity
  • Diet, Metabolism, and Disease
  • Hepatitis C virus research
  • Alcohol Consumption and Health Effects
  • Pancreatitis Pathology and Treatment

Zobair M. Younossi has contributed articles to a variety of leading medical journals, frequently publishing in:

  • Journal of Hepatology
  • Gastroenterology
  • Hepatology Communications
  • Hepatology
  • Clinical Gastroenterology and Hepatology

Some of the recent notable publications authored by Younossi include:

  • The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review, 2023, Hepatology
  • MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease, 2020, Gastroenterology
  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature, 2023, Hepatology
  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature, 2023, Journal of Hepatology
  • A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis, 2024, New England Journal of Medicine

Younossi has collaborated frequently with several researchers, including:

  • Maria Stepanova
  • Linda Henry
  • James M. Paik
  • Saleh A. Alqahtani
  • Pegah Golabi

Best Publications

  • Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

    Zobair M. Younossi;Zobair M. Younossi;Aaron B. Koenig;Dinan Abdelatif;Yousef Fazel

  • The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Michael Charlton

  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

    Zobair Younossi;Quentin M. Anstee;Milena Marietti;Timothy Hardy;Timothy Hardy

  • Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

    Christi A. Matteoni;Zobair M. Younossi;Terry Gramlich;Navdeep Boparai

  • Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

    G. Vernon;G. Vernon;A. Baranova;A. Baranova;Z. M. Younossi;Z. M. Younossi

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • The utility of radiological imaging in nonalcoholic fatty liver disease

    Sherif Saadeh;Zobair M. Younossi;Zobair M. Younossi;Erick M. Remer;Terry Gramlich

  • The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

    Chris Estes;Homie Razavi;Rohit Loomba;Zobair Younossi

  • Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

    Robert J. Wong;Maria Aguilar;Ramsey Cheung;Ramsey Cheung;Ryan B. Perumpail

  • Non-alcoholic fatty liver disease - A global public health perspective.

    Zobair M. Younossi;Zobair M. Younossi

  • The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.

    Zobair M. Younossi;Zobair M. Younossi;Pegah Golabi;Leyla de Avila;James Minhui Paik

  • Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

    Parambir S. Dulai;Siddharth Singh;Janki Patel;Meera Soni

  • Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

    Zobair Younossi;Zobair Younossi;Frank Tacke;Marco Arrese;Barjesh Chander Sharma

  • Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

    Zobair M. Younossi;Zobair M. Younossi;Maria Stepanova;Mariam Afendy;Yun Fang

  • The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

    Zobair M. Younossi;Deirdre Blissett;Robert Blissett;Linda Henry

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Nonalcoholic steatohepatitis

    Brian P. Mulhall;Zobair M. Younossi

Frequent Co-Authors

Zachary Goodman
Zachary Goodman Inova Fairfax Hospital
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Bruce R. Bacon
Bruce R. Bacon Saint Louis University
Sammy Saab
Sammy Saab University of California, Los Angeles
Sharon A. Hunt
Sharon A. Hunt Stanford University
Quentin M. Anstee
Quentin M. Anstee Newcastle University
Ira M. Jacobson
Ira M. Jacobson New York University
Graham R. Foster
Graham R. Foster Queen Mary University of London
Douglas T. Dieterich
Douglas T. Dieterich Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean committing to a traditional MD program. Many healthcare pathways and advanced degrees are now available online, with flexible formats to fit your schedule and learning style.

For nurses wanting to advance quickly, consider the shortest post master's dnp program or the shortest dnp program. These options allow experienced nurses to obtain a Doctor of Nursing Practice degree efficiently, expanding their leadership and clinical opportunities.

If you're looking to enter the healthcare field without a previous degree, an lpn program offers a streamlined route to become a Licensed Practical Nurse. This path is ideal for those seeking a hands-on patient care role with quicker entry into the workforce.

Mental health services are also in demand. The shortest pmhnp program prepares nurses to become Psychiatric Mental Health Nurse Practitioners through an accelerated route, making it easier to meet growing needs in mental health care.

Best Scientists Citing Zobair M. Younossi

Trending Scientists

Recently Published Articles